Human Papillomavirus Vaccinations: Provider Education to Enhance Vaccine Uptake

Document Type

Article

Publication Date

9-1-2023

Subject Area

Adult; Child; Female; Humans; Papillomavirus Vaccines; Papillomavirus Infections (prevention & control); Human Papillomavirus Viruses; Vaccination; Neoplasms (drug therapy); Health Knowledge, Attitudes, Practice

Abstract

Human papillomavirus (HPV) is the number one sexually transmitted infection (STI) worldwide. The Centers for Disease Control and Prevention (CDC) approximated that 92% of HPV-related cancers might be prevented by receiving the HPV 9-valent vaccine (Gardasil 9). The 2-dose HPV vaccine for children ages 11 to 12 years provides almost 100% protection against strains affiliated with cervical, vaginal, and vulvar cancers. Provider education is essential to decrease clinical knowledge deficits and increase vaccination uptake. Evidence-based provider recommendations expressed to eligible individuals improves vaccination rates. Evidence-based approaches for vaccine-hesitant parents involve using the presumptive announcement approach, asking for and addressing main concerns, and trying again if the parent initially declines. Seventy percent of parents who initially decide not to get their child vaccinated later agree to the vaccine or schedule a follow-up appointment. The CDC guidelines for HPV vaccinations, including the catch-up and adult guidelines, are reviewed. A clinical vignette with case scenarios and a Q&A quiz are included.

Publication Title

Clinical pediatrics

Volume

62

Issue

8

First Page

840

Last Page

848

Digital Object Identifier (DOI)

10.1177/00099228221147850

PubMed ID

36655653

E-ISSN

1938-2707

Language

eng

Link to Full Text

Share

COinS